Lung Cancer
A topic on our watch list — we track its coverage across 8 domains, including Pubmed Targeted, Kras Research and Industry News.
If Lung Cancer is on your watch list: what changed in the coverage, what the reporting asserts, and what the crowd is pricing.
What’s changed
- Pan-cancer single-cell atlas of immunotherapy response identifies ZNF385A as a regulator of immune evasion in small cell lung cancer. · Biochim Biophys Acta Mol Basis Dis · 2026-08-29
- One-pot SP-EXPAR-integrated CRISPR/Cas14a assay for highly specific and versatile detection of ctDNA mutations in lung cancer patients. · Anal Methods · 2026-08-24
- Impact of immunotherapy in the treatment of early-stage non-small lung cancer, melanoma, and colorectal cancer. · Immunotherapy · 2026-08-24
- Intratumoral microbiota in the growth of CRC and lung cancer: Comprehensive insights from etiology to therapy. · iScience · 2026-08-21
- Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer. · Ann Oncol · 2026-08-18
- Epigenetic profiling of circulating cell-free DNA for early detection and minimal residual disease assessment in lung cancer: a focus on DNA methylation · Frontiers Precision Oncology · 2026-08-27 · usually covers Precision Medicine
What the reporting says
It shows up alongside KRAS (65 — acquisition ×3), Immunotherapy (36), Colorectal Cancer (21), Egfr (15 — acquisition ×2), G12d (15), ctDNA (14), KRAS Mutant (13), FDA (23).
Two steps out: Pancreatic Cancer (through KRAS, 51 shared stories on the weaker link); MSI-H (through Immunotherapy, 36 shared stories on the weaker link); AI (through FDA, 23 shared stories on the weaker link); Cder (through FDA, 23 shared stories on the weaker link).
Tracked since Mar 26, with coverage on 55 separate days — concentrated in Oncology and Pubmed Targeted.